Conflict of Interest / Disclosure Policy

Whenever there is the potential for conflict of interest, details of funding, sponsorship, financial involvement and possible conflicts of interest will be prominently and fully disclosed.

Specific Disclosures for 2008:

Sponsorship for interviews at SCAI-ACC 2008 was provided by the Center for Health Education (CHE) through unrestricted joint educational grants from Scios, Astellas and Daiichi/Lilly. Sponsorship for interiews and presentations about 80 lead ECGs was provided by an educational grant from Heartscape Technologies. Sponsorship for the Optimizing Clinical Outcomes for ACS Patients series was provided by an educational grant from Schering Plough. Sponsorship for the RECORD 1, 2 and 3 interviews was provided by an unrestricted educational grant from Bayer.

Specific Disclosures for 2007:

Sponsorship for interviews this year at AHA 2007 and TCT 2007 was provided by the Center for Health Education (CHE) through unrestricted joint educational grants from Daiichi Sankyo Lilly, Genentech, Pfizer, Sanofi-Aventis, Schering-Plough and Scios. Sponsorship for the booth and interviews at ACC 2007 was provided by the Center for Health Education (CHE) through unrestricted joint educational grants from the Medicines Company, Merck, Schering-Plough and Scios.

Specific Disclosures for 2006:

Sponsorship for interviews at AHA 2006 was provided by the Center for Health Education (CHE) through an unrestricted education grant from Galaxo Smith Klein.

General Disclosures:

Dr. C. Michael Gibson, M.S., M.D., Editor-In-Chief

Currently there is no direct funding for the development and maintenance of this webpage. Some CME programs are sponsored as indicated.  We are currently seeking assistance from any interested parties.  The site is supported by volunteer efforts from Susan J. Marble and Dr. C. Michael Gibson.  Dr. Gibson is founder and director of PERFUSE (Percutaneous/Pharmacologic Endoluminal Revascularization For Unstable Syndromes & its Evaluation) and the TIMI Angiographic Core Laboraotories (non- profit entities) with over a decade of experience in cardiovascular research.  Over the years PERFUSE / TIMI  has received the research grant support from the following entities:

Government Agencies

The NIH  (HARP, PEARL); HCFA (Medicare CABG project)

Industry (in alphabetical order)

Acusphere; Astra (STEP AMI); Aventis / RPR (TIMI 11, ENTIRE); Bard (Perfusion balloon trial); Boston Scientific (Wallgraft studies); Bristol Meyer Squibb (HARP, CLARITY); British Biotech; Ciba Geigy (TIMI 9); Millenium Pharmaceuticals / COR Therapeutics (ESPRIT / TITAN / ADVANCE MI / PROTECT); Corgentech (PREVENT 4); DVI Guidant (Intermediate vessel atherectomy trial); Eli Lilly / Centocor (TIMI 14, SPEED); Genentech (TIMI 10, TIMI 12, LIMIT, VIVA); Merck (RESTORE, TACTICS, TARGET); Park Davis (AVERT); Percusurge, Point Biomedical; Smith Kline Beecham (TIMI 4); Sonus (Echogen trial); St Judes (Evaluation of Proximal Anastomotic Device); The Medicines Company (research support and consultancy); TIMI 3 Systems (the PLUS trial).

The TIMI Study Group has received funding from the following entities (in alphabetical order):

This website is owned and managed by Boston Clinical Research Institute  LLC. Contact the managing editor: smarble@clinicaltrialresults.org .

Employees paid by Pixcella LLC for their time in filming, video-editing, managing the website:

Erin Lord

Scott Williams

Lauren Ciaglo

Katherine Ogando

Alexandra Palmer

Alexandra Almonacid

Pillar Almonacid

Leah Biller